Phase I
Glypican-3 ADC^
--Hepatocellular Carcinoma
Anti-TIGIT^
--Solid Tumors
Anti-GITR^
--Solid Tumors
Cabiralizumab✦^
--Solid Tumors
Anti-CD73^
--Solid Tumors
Anti-OX40^
--Solid Tumors
Anti-LAG3^
--Solid Tumors & Hematologic Malignancies
IDO Inhibitor^
--Solid Tumors
Mesothelin-ADC^
--Solid Tumors
HuMax-IL8
--Solid Tumors
Anti-HER2✦ ++
--Breast Cancer
BET Inhibitor
--Solid Tumors
Ulocuplumab
--Hematologic Malignancies
Lirilumab✦^
--Solid Tumors
Lirilumab✦ + Empliciti✦
--Multiple Myeloma
Urelumab + Empliciti✦
--Multiple Myeloma
Opdivo✦
--Solid Tumors & Hematologic Malignancies
Opdivo✦ + Yervoy✦
--Solid Tumors
Opdivo✦
--Pediatric
Phase II
Opdivo✦
--Non-Hodgkin Lymphoma (Follicular Lymphoma)
--Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma)
--MSI+ Colon
--Ovarian✦#
--2nd line Hepatocellular Carcinoma
--CNS Lymphoma
Anti-LAG3 + Opdivo✦
--Solid Tumors
Lirilumab✦
--Hematologic Malignancies
Urelumab + Opdivo✦
--Solid Tumors & Hematologic Malignancies
Anti-Fucosyl GM1^
--Small Cell Lung Cancer
Empliciti
--1st line Multiple Myeloma Pomalidomide Combo
Yervoy✦
--Adolescent Melanoma
Sprycel✦
--Pediatric
Phase III
Opdivo✦
--Adjuvant Melanoma
--2nd line Small Cell Lung Cancer
--Unresectable Non-Small Cell Lung Cancer
--1st line Head & Neck
--3rd line Gastric#
--1st line Glioblastoma
--2nd line Glioblastoma
--1st line Hepatocellular Carcinoma
--Adjuvant Bladder
--2nd line Esophageal
--Adjuvant Esophageal/ Gastroesophageal
Opdivo✦ + Yervoy✦
--1st line Non-Small Cell Lung Cancer
--1st line Small Cell Lung Cancer
--1st line Renal Cell Carcinoma
--1st line Head & Neck
--1st line Gastric
--1st line Esophageal
--1st line Mesothelioma
Opdivo✦ + Empliciti✦
--Multiple Myeloma
Empliciti✦
--1st line Multiple Myeloma Revlimid Combo
PROSTVAC✦ ++
--Metastatic Castration - Resistant Prostate Cancer
Approved Indications
Opdivo✦
--Previously treated Metastatic Melanoma
--1st line BRAF wild-type Metastatic Melanoma
--Melanoma across BRAF status
--Previously treated Metastatic Squamous Non-Small Cell Lung Cancer
--Previously treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
--Previously treated advanced Renal Cell Carcinoma
--Advanced Hodgkin Lymphoma
--Previously treated Metastatic Head & Neck Cancer
--Previously treated Metastatic Urothelial Carcinoma◊
Opdivo✦ + Yervoy✦
--BRAF wild-type Metastatic Melanoma
--Melanoma across BRAF status
Yervoy✦
--Metastatic Melanoma
--Adjuvant Melanoma
Empliciti✦
--Relapsed/Refractory Multiple Myeloma Revlimid Combo
Sprycel✦
--1st line Chronic Myelogenous Leukemia
--Refractory Chronic Myelogenous Leukemia
Phase I
TYK2 Inhibitor (2)
--Autoimmune Diseases
PD-L1 Inhibitor
--Autoimmune Diseases
BTK Max
--Rheumatoid Arthritis
S1P1
--Autoimmune Diseases
Anti-IP10
--Ulcerative Colitis
Anti-PD-L1
--Sepsis
Opdivo✦
--Sepsis
Phase II
Lulizumab
--Lupus
BTK Inhibitor
--Rheumatoid Arthritis
Anti-CD40L
--Autoimmune Disease
TYK2 Inhibitor (1)
--Psoriasis
Phase III
Orencia
--Lupus Nephritis
--Psoriatic Arthritis
--Sjogren’s Syndrome
Nulojix
--Switch from CNI Renal Transplant
Approved Indications
Orencia
--Rheumatoid Arthritis Intravenous
--Rheumatoid Arthritis Subcutaneous
--Rheumatoid Arthritis Auto Injector
--Juvenile Idiopathic Arthritis
--Early Rheumatoid Arthritis
Nulojix
--De Novo Renal Transplant
Phase I
Factor XIa Inhibitor
--Thrombosis
Phase II
Nitroxyl Donor
--Heart Failure
PAR4 Antagonist
--Thrombosis/Stroke
Phase III
Eliquis✦
--Pediatric VTE Treatment
Approved Indications
Eliquis✦
--VTE Prevention, Orthopedic Surgery
--Stroke Prevention in Atrial Fibrillation
--VTE Treatment